205 related articles for article (PubMed ID: 35437610)
1. Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant.
Wang Y; Wang T; Yu Y; Wang Q; Yan Y; Li R; Sun Q; Xiong W; Lyu R; Yu Z; Liu W; Sui W; Huang W; Wang H; Li C; Wang J; Zou D; An G; Wang J; Qiu L; Yi S
Ann Hematol; 2022 Jun; 101(6):1201-1210. PubMed ID: 35437610
[TBL] [Abstract][Full Text] [Related]
2. Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse.
Hu R; Wei W; Mian A; Gonter-Aubin K; Kabel C; Mato A; Stephens DM; Hanlon A; Khajavian S; Shadman M; Brander D; Madanat Y; Park JH; Tallman M; Pinilla-Ibarz J; Hill BT
Eur J Haematol; 2022 May; 108(5):379-382. PubMed ID: 35043475
[TBL] [Abstract][Full Text] [Related]
3. [Clinical and molecular characteristics and prognosis of classical hairy cell leukemia and hairy cell leukemia variant].
Wei C; Jin XX; Cai H; Wang X; Zhuang JL; Zhou DB
Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):416-421. PubMed ID: 37032137
[No Abstract] [Full Text] [Related]
4. Hairy cell leukemia and variant in Taiwan: report of a variant case and literature review.
Hsieh YC; Chang ST; Chuang SS; Lu CL; Tsao CJ; Lin CN; Li CY
Int J Clin Exp Pathol; 2011 Jan; 4(2):183-9. PubMed ID: 21326814
[TBL] [Abstract][Full Text] [Related]
5. Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment.
Maitre E; Cornet E; Troussard X
Am J Hematol; 2019 Dec; 94(12):1413-1422. PubMed ID: 31591741
[TBL] [Abstract][Full Text] [Related]
6. Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria.
Shao H; Calvo KR; Grönborg M; Tembhare PR; Kreitman RJ; Stetler-Stevenson M; Yuan CM
Leuk Res; 2013 Apr; 37(4):401-409. PubMed ID: 23347903
[TBL] [Abstract][Full Text] [Related]
7. Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment.
Troussard X; Cornet E
Am J Hematol; 2017 Dec; 92(12):1382-1390. PubMed ID: 29110361
[TBL] [Abstract][Full Text] [Related]
8. Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia.
Cornet E; Delmer A; Feugier P; Garnache-Ottou F; Ghez D; Leblond V; Levy V; Maloisel F; Re D; Zini JM; Troussard X;
Ann Hematol; 2014 Dec; 93(12):1977-83. PubMed ID: 24994538
[TBL] [Abstract][Full Text] [Related]
9. Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment.
Robak T
Cancer Treat Rev; 2011 Feb; 37(1):3-10. PubMed ID: 20558005
[TBL] [Abstract][Full Text] [Related]
10. Refractory and relapsed hairy-cell leukemia (HCL): casting light on promising experimental drugs in clinical trials.
Robak T; Robak P
Expert Opin Investig Drugs; 2023 Apr; 32(4):311-324. PubMed ID: 36931901
[TBL] [Abstract][Full Text] [Related]
11. The pharmacological management of hairy cell leukemia.
Ramos Perez J; Ravandi-Kashani F
Expert Opin Pharmacother; 2020 Aug; 21(11):1337-1344. PubMed ID: 32378970
[TBL] [Abstract][Full Text] [Related]
12. Adverse event rates and economic burden associated with purine nucleoside analogs in patients with hairy cell leukemia: a US population-retrospective claims analysis.
Epperla N; Pavilack M; Olufade T; Bashyal R; Li J; Kabadi SM; Yuce H; Andritsos L
Orphanet J Rare Dis; 2020 Feb; 15(1):47. PubMed ID: 32054500
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological spectrum of hairy-cell leukemia: A single-center study with brief review of Indian literature.
Gupta R; Yadav S; Mittal N; Rahman K; Sharma A; Gupta A; Nityan S
J Cancer Res Ther; 2020; 16(1):120-126. PubMed ID: 32362621
[TBL] [Abstract][Full Text] [Related]
14. Hairy cell leukaemia-variant: Disease features and treatment.
Matutes E; Martínez-Trillos A; Campo E
Best Pract Res Clin Haematol; 2015 Dec; 28(4):253-63. PubMed ID: 26614904
[TBL] [Abstract][Full Text] [Related]
15. CD103-CD23+ classical hair cell leukemia: A case report and review of the literature.
Zhao HL; Cui HH; Jin LF; Zhao M; Shen WZ
Medicine (Baltimore); 2021 Dec; 100(51):e28262. PubMed ID: 34941102
[TBL] [Abstract][Full Text] [Related]
16. Hairy Cell Leukemia (HCL) and HCL Variant: Updates and Spotlights on Therapeutic Advances.
Paillassa J; Maitre E; Troussard X
Curr Oncol Rep; 2022 Sep; 24(9):1133-1143. PubMed ID: 35403971
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up after rituximab plus bendamustine in a patient with relapsed or refractory hairy cell leukemia variant: A case report.
Imoto N; Koyama D; Sugiura I; Kurahashi S
Medicine (Baltimore); 2021 Feb; 100(5):e24457. PubMed ID: 33592897
[TBL] [Abstract][Full Text] [Related]
18. Hairy cell leukemia 2024: Update on diagnosis, risk-stratification, and treatment-Annual updates in hematological malignancies.
Troussard X; Maître E; Paillassa J
Am J Hematol; 2024 Apr; 99(4):679-696. PubMed ID: 38440808
[TBL] [Abstract][Full Text] [Related]
19. Differential Expression of CD43, CD81, and CD200 in Classic Versus Variant Hairy Cell Leukemia.
Salem DA; Scott D; McCoy CS; Liewehr DJ; Venzon DJ; Arons E; Kreitman RJ; Stetler-Stevenson M; Yuan CM
Cytometry B Clin Cytom; 2019 Jul; 96(4):275-282. PubMed ID: 31077558
[TBL] [Abstract][Full Text] [Related]
20. Current treatment options in hairy cell leukemia and hairy cell leukemia variant.
Robak T
Cancer Treat Rev; 2006 Aug; 32(5):365-76. PubMed ID: 16781083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
